JP2015010091A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015010091A5 JP2015010091A5 JP2014124999A JP2014124999A JP2015010091A5 JP 2015010091 A5 JP2015010091 A5 JP 2015010091A5 JP 2014124999 A JP2014124999 A JP 2014124999A JP 2014124999 A JP2014124999 A JP 2014124999A JP 2015010091 A5 JP2015010091 A5 JP 2015010091A5
- Authority
- JP
- Japan
- Prior art keywords
- ppm
- crystalline
- value
- powder
- values
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361840703P | 2013-06-28 | 2013-06-28 | |
| US61/840,703 | 2013-06-28 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015010091A JP2015010091A (ja) | 2015-01-19 |
| JP2015010091A5 true JP2015010091A5 (enExample) | 2016-08-04 |
| JP6110817B2 JP6110817B2 (ja) | 2017-04-05 |
Family
ID=51136530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014124999A Expired - Fee Related JP6110817B2 (ja) | 2013-06-28 | 2014-06-18 | 大環状キナーゼ阻害剤の固体形態 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9637500B2 (enExample) |
| EP (1) | EP3013835B1 (enExample) |
| JP (1) | JP6110817B2 (enExample) |
| AR (1) | AR096759A1 (enExample) |
| CA (1) | CA2916605C (enExample) |
| ES (1) | ES2656189T3 (enExample) |
| TW (1) | TW201504246A (enExample) |
| WO (1) | WO2014207606A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3183256A4 (en) * | 2014-08-20 | 2018-05-30 | Teligene Ltd. | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| WO2016026423A1 (en) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| SG10201913200XA (en) | 2015-07-31 | 2020-03-30 | Pfizer | Crystalline form of lorlatinib free base |
| JP2018529719A (ja) | 2015-09-30 | 2018-10-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ |
| ES2812336T3 (es) | 2016-03-03 | 2021-03-16 | Shenzhen Targetrx Inc | Macrocíclico y composición que comprende el mismo |
| CA3019905C (en) | 2016-04-08 | 2022-08-23 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| SI3694863T1 (sl) * | 2017-10-10 | 2023-10-30 | Pfizer Inc. | Kristalna oblika hidrata proste baze lorlatiniba |
| US11179412B2 (en) | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
| WO2019209633A1 (en) | 2018-04-23 | 2019-10-31 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| JP7347852B2 (ja) * | 2018-11-28 | 2023-09-20 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | 重水素化大環状化合物の調製方法 |
| CN109651398B (zh) * | 2019-01-25 | 2021-07-30 | 安庆多辉生物科技有限公司 | 一种合成劳拉替尼的溴代物中间体及催化合成劳拉替尼的方法 |
| US12391708B2 (en) | 2019-07-18 | 2025-08-19 | Tapi Croatia Industries Ltd | Crystalline Lorlatinib : fumaric acid and solid state form thereof |
| CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
| CN110483551B (zh) * | 2019-08-30 | 2021-10-22 | 北京赛思源生物医药技术有限公司 | 一种劳拉替尼游离碱的晶体 |
| EP4041396A1 (en) | 2019-10-10 | 2022-08-17 | Sandoz AG | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
| WO2021226208A2 (en) | 2020-05-05 | 2021-11-11 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| KR102698413B1 (ko) | 2020-05-05 | 2024-08-26 | 뉴베일런트, 아이엔씨. | 헤테로방향족 거대환식 에터 화학치료제 |
| CN112724077B (zh) * | 2020-12-29 | 2023-07-11 | 武汉利昌医药科技有限公司 | 一种劳拉替尼中间体的合成方法 |
| CN113292496B (zh) * | 2021-05-17 | 2023-03-10 | 安徽联创生物医药股份有限公司 | 一种劳拉替尼中间体的合成方法 |
| TW202320768A (zh) | 2021-10-01 | 2023-06-01 | 美商努法倫特公司 | 雜芳族大環醚化合物之固體形式、醫藥組成物及製備 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2796967C (en) | 2010-05-04 | 2015-12-01 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| CA2863892C (en) | 2012-03-06 | 2016-08-30 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
-
2014
- 2014-06-17 CA CA2916605A patent/CA2916605C/en active Active
- 2014-06-17 EP EP14736454.1A patent/EP3013835B1/en not_active Not-in-force
- 2014-06-17 US US14/898,582 patent/US9637500B2/en active Active
- 2014-06-17 WO PCT/IB2014/062296 patent/WO2014207606A1/en not_active Ceased
- 2014-06-17 ES ES14736454.1T patent/ES2656189T3/es active Active
- 2014-06-18 JP JP2014124999A patent/JP6110817B2/ja not_active Expired - Fee Related
- 2014-06-26 AR ARP140102433A patent/AR096759A1/es unknown
- 2014-06-27 TW TW103122400A patent/TW201504246A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016065042A5 (enExample) | ||
| JP2014526498A5 (enExample) | ||
| JP2017039702A5 (enExample) | ||
| JP2018024682A5 (enExample) | ||
| WO2016087665A3 (en) | Compounds for treating cystic fibrosis | |
| JP2015044837A5 (enExample) | ||
| UA109868C2 (ru) | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) | |
| JP2014162794A5 (enExample) | ||
| JP2011168587A5 (enExample) | ||
| NZ757221A (en) | Crystalline forms of diazabicyclooctane derivative and production process thereof | |
| JP2010516662A5 (enExample) | ||
| FI4349406T3 (fi) | 6-karboksi-2-(3,5-dikloorifenyyli)-bentsoksatsolin kiteisiä kiinteitä muotoja käytettäväksi lääkkeenä | |
| JP2013521273A5 (enExample) | ||
| EP2665694A1 (en) | Process for the manufacture of 2,3,3,3- tetrafluoropropene by gas phase fluorination of pentachloropropane | |
| EP4241772A3 (en) | Process for the preparation of compounds useful for treating spinal muscular atrophy | |
| JP2019510768A5 (enExample) | ||
| PH12017502007A1 (en) | Crystals of azabicyclic compound | |
| WO2015145415A3 (en) | Ibrutinib solid forms and production process therefor | |
| RU2016146119A (ru) | Новый кристалл тетрациклического соединения | |
| JP2013503134A5 (enExample) | ||
| WO2015171526A3 (en) | Tricyclic pyrazolopyridine compounds | |
| WO2011029547A8 (en) | Isoxazolidine derivatives | |
| JP2020536893A5 (enExample) | ||
| JP2016204373A5 (enExample) | ||
| JP2015522037A5 (enExample) |